Search details
1.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Article
in English
| MEDLINE | ID: mdl-30786188
2.
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.
Nature
; 527(7579): 472-6, 2015 Nov 26.
Article
in English
| MEDLINE | ID: mdl-26560033
3.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat
; 183(1): 227-237, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32613539
4.
Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting.
J Am Coll Nutr
; 38(1): 1-14, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30511901
5.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer
; 123(19): 3843-3854, 2017 Oct 01.
Article
in English
| MEDLINE | ID: mdl-28558150
6.
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Oncologist
; 22(3): 245-254, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28220020
7.
Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.
Support Care Cancer
; 25(3): 701-708, 2017 03.
Article
in English
| MEDLINE | ID: mdl-27830395
8.
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
BMC Cancer
; 15: 267, 2015 Apr 11.
Article
in English
| MEDLINE | ID: mdl-25885598
9.
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Oncologist
; 19(4): 318-27, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24682463
10.
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
Breast Cancer Res Treat
; 146(2): 321-8, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24699910
11.
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
Breast Cancer Res Treat
; 139(3): 705-15, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23774991
12.
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
Breast Cancer Res Treat
; 140(2): 341-51, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23877339
13.
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Breast Cancer Res Treat
; 141(3): 429-35, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-24068539
14.
New developments in metastatic breast cancer: integrating recent data into clinical practice.
Clin Adv Hematol Oncol
; 11(10 Suppl 16): 1-18; quiz 19, 2013.
Article
in English
| MEDLINE | ID: mdl-24892840
15.
Cancer Epidemiology in the Northeastern United States (2013-2017).
Cancer Res Commun
; 3(8): 1538-1550, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37583435
16.
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Lancet
; 377(9769): 914-23, 2011 Mar 12.
Article
in English
| MEDLINE | ID: mdl-21376385
17.
Incremental increase in VEGFR1⺠hematopoietic progenitor cells and VEGFR2⺠endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Breast Cancer Res Treat
; 132(1): 235-42, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-22160642
18.
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Support Care Cancer
; 20(11): 2661-8, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-22382588
19.
Connecting copper and cancer: from transition metal signalling to metalloplasia.
Nat Rev Cancer
; 22(2): 102-113, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34764459
20.
Novel treatment options in the management of metastatic breast cancer.
Clin Adv Hematol Oncol
; 9(5 Suppl 10): 1-16, 2011 May.
Article
in English
| MEDLINE | ID: mdl-21738118